The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- FARMACOVIGILÂNCIA avançada: ““Excelente! Organizada e abrangente !”
- Study on the deployment of AI in healthcare Final report
- Boas Práticas de Fabrico . GMP 2025: “Formação foi muito útil a nível de aplicabilidade “
- Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties
- COMMISSION IMPLEMENTING REGULATION (EU) 2025/2086 of 17 October 2025
- Main root causes of shortages: Analysis of reported root causes during 2022 & 2023
- EUDAMED Release note v 2.18.0
- The ICH E2D(R1) Guideline reaches Step 4 of the ICH Process

